Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Baxter
Daiichi Sankyo
Colorcon
Chubb
US Department of Justice

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 9,707,257

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,707,257
Title:Anti-HIV group I introns and uses thereof in treating HIV infections
Abstract: Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections.
Inventor(s): Fraser, Jr.; Malcolm James (Granger, IN)
Assignee: The University of Notre Dame (Notre Dame, IN)
Application Number:13/096,626
Patent Claims:see list of patent claims

Details for Patent 9,707,257

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up The University of Notre Dame (Notre Dame, IN) ➤ Sign Up RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up The University of Notre Dame (Notre Dame, IN) ➤ Sign Up RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up The University of Notre Dame (Notre Dame, IN) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Harvard Business School
Teva
Moodys
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.